Tags

Type your tag names separated by a space and hit enter

The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.
Bone Marrow Transplant. 1999 Jan; 23(1):45-51.BM

Abstract

At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy.

Authors+Show Affiliations

Department of Medicine, University of Toronto, Mount Sinai Hospital, Ontario, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

10037050

Citation

Humar, A, et al. "The Clinical Utility of CMV Surveillance Cultures and Antigenemia Following Bone Marrow Transplantation." Bone Marrow Transplantation, vol. 23, no. 1, 1999, pp. 45-51.
Humar A, O'Rourke K, Lipton J, et al. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Bone Marrow Transplant. 1999;23(1):45-51.
Humar, A., O'Rourke, K., Lipton, J., Messner, H., Meharchand, J., Mahony, J., Walker, I., Wasi, P., McGeer, A., Moussa, G., Chua, R., & Mazzulli, T. (1999). The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Bone Marrow Transplantation, 23(1), 45-51.
Humar A, et al. The Clinical Utility of CMV Surveillance Cultures and Antigenemia Following Bone Marrow Transplantation. Bone Marrow Transplant. 1999;23(1):45-51. PubMed PMID: 10037050.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. AU - Humar,A, AU - O'Rourke,K, AU - Lipton,J, AU - Messner,H, AU - Meharchand,J, AU - Mahony,J, AU - Walker,I, AU - Wasi,P, AU - McGeer,A, AU - Moussa,G, AU - Chua,R, AU - Mazzulli,T, PY - 1999/2/26/pubmed PY - 1999/2/26/medline PY - 1999/2/26/entrez SP - 45 EP - 51 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 23 IS - 1 N2 - At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/10037050/The_clinical_utility_of_CMV_surveillance_cultures_and_antigenemia_following_bone_marrow_transplantation_ L2 - https://doi.org/10.1038/sj.bmt.1701525 DB - PRIME DP - Unbound Medicine ER -